目的 探討燈盞細(xì)辛注射液聯(lián)合注射用尤瑞克林治療急性腦梗死的臨床療效。方法 選取2019年3月—2020年12月在天津市中醫(yī)藥研究院附屬醫(yī)院就診的84例急性腦梗死患者為研究對(duì)象，按照隨機(jī)數(shù)字表法將84例患者分為對(duì)照組和治療組，每組各42例。對(duì)照組患者靜脈滴注注射用尤瑞克林，0.15 PNA加入100 mL氯化鈉溶液中，1次/d。治療組患者在對(duì)照組治療的基礎(chǔ)上靜脈滴注燈盞細(xì)辛注射液，20 mL加入250 mL生理鹽水中，1次/d。兩組患者連續(xù)治療2周。考察了兩組的臨床療效，比較兩組患者的NIHSS評(píng)分、血清因子水平和血液流變學(xué)指標(biāo)。結(jié)果 治療后，治療組患者的總有效率（95.24%）比對(duì)照組（80.95%）高，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的NIHSS評(píng)分顯著降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且治療組患者的NIHSS評(píng)分明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的葉酸（FA）水平明顯升高，基質(zhì)金屬蛋白酶-3（MMP-3）、內(nèi)皮素-1（ET-1）水平明顯降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組的FA水平高于對(duì)照組，MMP-3、ET-1水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的全血黏度、血小板黏附性、纖維蛋白原顯著降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組患者的全血黏度、血小板黏附性、纖維蛋白原低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 燈盞細(xì)辛注射液聯(lián)合注射用尤瑞克林可提高急性腦梗死的療效，改善血管內(nèi)皮功能和血液流變學(xué)，改善神經(jīng)功能，且安全性良好。

Objective To investigate the clinical efficacy of Dengzhan Xixin Injection combined with Urinary Kallidinogenase for injection in treatment of acute cerebral infarction.Methods Patients (84 cases) with acute cerebral infarction in Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital from March 2019 to December 2020 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA added into normal saline 100 mL, once daily. Patients in the treatment group were iv administered with Dengzhan Xixin Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores, serum factors level, and hemorheology indexes in two groups were compared.Results After treatment, the total effective rate of the treatment group (95.24%) was higher than that of the control group (80.95%), and the difference was statistically significant (P<0.05). After treatment, the NIHSS scores of two groups were significantly decreased (P<0.05), and the NIHSS score of the treatment group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the level of FA in two groups was significantly increased, but the levels of MMP-3 and ET-1 in two groups were significantly decreased, and the difference was statistically significant (P<0.05). After treatment, the level of FA in the treatment group was higher than that ole blood viscosity, platelet adhesion, and fibrinogen of the two groups were significantly decreased, and the difference was statistically significant (P<0.05). After treatment, the whole blood viscosity, platelet adhesion, and fibrinogen of the treatment group were lower than those of the control group, and the difference was statistically significant (P<0.05).Conclusion Dengzhan Xixin Injection combined with Urinary Kallidinogenase for injection can improve the curative effect of acute cerebral infarction, improve vascular endothelial function and hemorheology, improve neurological function, with good safety.

R971

天津市科技計(jì)劃項(xiàng)目（18ZXDBSY00080）